Financial StabilityThe company may have sufficient capital to fund operations into 2H25.
Product InnovationThe Co-Dx PCR Pro platform consists of a compact and robust real-time PCR instrument operated at point-of-care or in at-home settings via a smartphone interface.
Regulatory ProgressThe company submitted its emergency use authorization (EUA) application for Co-Dx PCR Pro instrument, mobile app, and Co-Dx COVID-19 test kit to the FDA in December 2023 and the application is under FDA review.